Globus Medical, Inc.
GMED Healthcare Medical Devices
Globus Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 16.7% from fiscal 2024.
- Revenue
- −0.69%
- EPS
- +19.3%
- Free cash flow
- +10.1%
Quarter to September 2026, against a year earlier
Follow GMED
Alert me
Globus Medical, Inc. (GMED) P/B ratio
As of 5 November 2026, Globus Medical, Inc. (GMED) trades at a P/B ratio of 2.3×. Over the past ten years it has ranged from 1.2× (November 2023) to 5.4× (June 2018); the current reading is higher than 12% of that period. That is below the Medical Devices industry median of 2.5× and in line with the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 2.6× | (3.94%) |
| FY2024 | 2.7× | 78.71% |
| FY2023 | 1.5× | (62.23%) |
| FY2022 | 4.0× | (4.69%) |
| FY2021 | 4.2× | (2.15%) |
| FY2020 | 4.3× | 2.54% |
| FY2019 | 4.2× | 16.49% |
| FY2018 | 3.6× | (16.76%) |
| FY2017 | 4.3× | 50.66% |
| FY2016 | 2.8× | (22.91%) |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 2.1× | (6.38%) |
| Jun 2026 | 2.2× | (9.20%) |
| Mar 2026 | 2.5× | (4.53%) |
| Dec 2025 | 2.6× | 47.42% |
| 43 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| BIO Bio-Rad Laboratories, Inc. compare | 1.3× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 1.3× |
| GMED Globus Medical, Inc. | 2.3× |
| SNN Smith & Nephew SNATS, Inc. compare | 2.8× |
| BRKR Bruker Corporation compare | 3.7× |
| PODD Insulet Corporation compare | 7.6× |
| PEN Penumbra, Inc. compare | 8.0× |
| TXG 10x Genomics compare | 9.2× |
| GKOS Glaukos Corporation compare | 18.1× |
| Medical Devices industry median | 2.5× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on GMED
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement